Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.
1. A method of treating a neuron inflammation condition in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the compound having the following formula:
wherein the neuron inflammation condition is amyotrophic lateral sclerosis (ALS), Huntington's Disease, Parkinson's disease (PD), ischemic stroke, or a condition associated with prion disease.
2. The method of claim 1 , wherein the neuron inflammation condition is ALS.
3. The method of claim 1 , wherein the neuron inflammation is Huntington's Disease.
4. The method of claim 1 , wherein the neuron inflammation is Parkinson's disease.
5. The method of claim 1 , wherein the neuron inflammation condition is ischemic stroke.
6. The method of claim 1 , wherein the neuron inflammation condition is associated with prion disease.
7. The method of claim 2 , wherein the compound is administered intraperitoneally and/or intravenously.
8. The method of claim 1 , wherein the compound is administered transdermally.
9. The method of claim 1 , wherein the compound is administered by inhalation.
10. The method of claim 1 , wherein the compound is administered at a dose between about 1 mg and about 1000 mg per day.
11. The method of claim 1 , where in the compound is administered at a dose of about 10, about 20, about 30, about 50, about 100, or about 500 mg per day.
12. The method of claim 2 , further comprising co-administering a second compound selected from CD4+; siRNA; miRNA that ameliorates ALS; glial morphology modifier; SOD1 control; and Riluzole.
13. The method of claim 2 , further comprising co-administering a second compound selected from an antibody targeting drug that ameliorates ALS and an anti-inflammatory targeting drug that ameliorates ALS.
14. The method of claim 1 , further comprising co-administering a second compound selected from a targeting drug that ameliorates neurodegeneration associated with amyloidosis or tauopathies.
15. The method of claim 4 , further comprising co-administering a second compound selected from an alpha synuclein targeting drug that ameliorates PD and a Parkinson's targeting drug that ameliorates PD.
16. The method of claim 1 , wherein the compound is administered at a dose between about 1 mg and about 70 mg per day.
17. The method of claim 1 , wherein the compound is administered orally.